Carles Pericay

Carles Pericay is an expert in Oncology at Corporació Sanitària Parc Taulí (Spain). As of April 2026, ScienceLeadR ranks Carles Pericay in the top 1% of experts worldwide for Rectal Diseases, Intestinal Neoplasms and Gastrointestinal Neoplasms. Carles Pericay has authored 208 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 1 of them ongoing. SLR score: 651 (community average: 125). How the SLR is computed.

Oncology

Subspecialties: Gastroenterology - Pharmacy - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on April 29, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026

Source: PubMed

University Hospital Mútua de Terrassa

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 208

Citations

Citations: 7 403 1st author: 21 Last author: 17 Unique author: 0

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year	Citations
Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study). PMID 42026347 — radiotherapy, quality of life, safety, neoplasms, adenocarcinoma, chemoradiotherapy, rectal neoplasms, morbidity, transanal endoscopic surgery	Int J Colorectal Dis	2026	0
Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis. PMID 41415036 — quality of life, safety, trifluridine, neoplasms, bevacizumab, decision making, therapeutics, colorectal neoplasms	J Pharm Policy Pract	2025	0
Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial. PMID 40434784 — surgical procedures, operative, neoplasms, chemoradiotherapy, rectal neoplasms, therapeutics	JAMA Surg	2025	9
Long-term prognostic value of apoptotic index in colorectal cancer: a 5-year multicentre cohort study. PMID 40000339 — neoplasms, pathology, cohort studies, colon, biomarkers, rectal neoplasms, colorectal neoplasms, apoptosis, artificial intelligence, prognosis, dna nucleotidylexotransferase, colonic neoplasms	Pathology	2025	0
Negative hyperselection beyond RAS: is a key tool for choosing the optimal maintenance treatment in metastatic colorectal cancer? PMID 39554573 — genes, ras, neoplasms, maintenance, panitumumab, therapeutics, colorectal neoplasms	J Gastrointest Oncol	2024	0

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 1

By phase:

Phase 2 7

N/A 4

Phase 3 4

Phase 1/Phase 2 1

By status:

Completed 13

Unknown 2

Not yet recruiting 1

By type:

Interventional 14

Observational 2

By Monocentric/Multicentric:

monocentric 11

multicentric2to4 0

multicentric5to9 0

multicentricup10 5

Main Topics

Digestive System Diseases 15

Cohort/Consortium Investigators 5

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0 M0 Rectal Cancer (TAUTEM T1 Study) NCT06450574 — radiotherapy, transanal endoscopic microsurgery, quality of life, neoplasms, adenocarcinoma, chemoradiotherapy, neoadjuvant therapy, rectal neoplasms, diagnosis, morbidity, microsurgery, therapeutics, capecitabine, transanal endoscopic surgery	Phase 3	Not yet recruiting	2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice